Hospitals and Other Providers Ask HHS to Halt Lilly and Merck’s Clampdowns on 340B; Companies Defend Their Positions
The U.S. Health and Human Services Department (HHS) should halt drug manufacturers Eli Lilly and Merck’s recent separate actions to curtail or investigate 340B drug discounts on products dispensed to patients by covered entities’ contract pharmacies, an umbrella group for associations that represent 340B covered entities says.
“It is in the public interest that the [Trump] Administration act swiftly and firmly to stop these actions,” the 340B Coalition said in a July 16 letter to HHS Secretary Alex Azar. The coalition’s annual summer meeting, being held virtually for the first time due to the COVID-19 pandemic, begins July 20.
×